Han HD1, Byeon Y1, Jang JH2, Jeon HN1, Kim GH1, Kim MG1, Pack CG3, Kang TH1, Jung ID1, Lim YT4, Lee YJ5, Lee JW6, Shin BC7, Ahn HJ8, Sood AK9,10,11, Park YM1.
Sci Rep. 2016 Dec 2;6:38348. doi: 10.1038/srep38348.Dentritic cell (DC)-based cancer immunotherapy faces challenges in both efficacy and practicality. However, DC-based vaccination requires multiple injections and elaborates ex vivo manipulation, which substantially limits their use. Therefore, we sought to develop a chitosan nanoparticle (CH-NP)-based platform for the next generation of vaccines to bypass the ex vivo manipulation and induce immune responses via active delivery of polyinosinic-polycytidylic acid sodium salt (poly I:C) to target Toll-like receptor 3 (TLR3) in endosomes. Read More